Science means little if it does not reach the people who need it most
En una época en que la ciencia a menudo parece distante de quienes más la necesitan, una joven bióloga colombiana de veintidós años ha cruzado el umbral de una de las sociedades científicas más selectas del mundo. María del Rosario Yanett Anillo, oriunda de Samaria, fue admitida por invitación en Sigma Xi —fundada en 1886 y hogar de más de doscientos laureados con el Nobel— no como destino, sino como confirmación de un camino que comenzó con el diagnóstico de su hermana y se extendió hacia las poblaciones más vulnerables de América Latina. Su historia recuerda que la vocación científica más poderosa no nace en los laboratorios, sino en el amor.
- A los veintidós años, Anillo ingresa a una sociedad que ha tardado décadas en reconocer a investigadores de toda una vida, subvirtiendo la idea de que la excelencia científica es privilegio de la madurez.
- Las enfermedades raras y huérfanas que estudia afectan a poblaciones latinoamericanas que la industria farmacéutica ignora por falta de rentabilidad, creando una urgencia ética que su trabajo busca visibilizar.
- Su libro, sus premios internacionales y su voluntariado desde los trece años en la Cruz Roja colombiana revelan una tensión resuelta: la ciencia no puede permanecer encerrada en el laboratorio si pretende ser justa.
- Con reconocimientos acumulados en apenas meses —el International Leader Award en diciembre de 2025 y el máximo galardón de la Federación Interamericana de Periodismo en febrero de 2026— su trayectoria se acelera hacia una influencia regional que apenas comienza.
A los veintidós años, María del Rosario Yanett Anillo, bióloga de Samaria, Colombia, fue admitida en Sigma Xi, la sociedad científica fundada en 1886 que admite miembros únicamente por invitación y que cuenta entre sus filas a más de doscientos premios Nobel, entre ellos Albert Einstein y Linus Pauling. Graduada de la Universidad de Fordham en Nueva York, Anillo construyó a edad temprana un portafolio de investigación centrado en genética, enfermedades infecciosas y sistemas de salud en América Latina que llamó la atención del comité de selección.
El origen de su vocación es profundamente personal: cuando su hermana menor fue diagnosticada con síndrome de Turner, una condición cromosómica, la curiosidad intelectual de Anillo se transformó en propósito. Desde entonces ha dedicado su trabajo a las enfermedades genéticas, el cáncer y las enfermedades raras —llamadas huérfanas porque la industria farmacéutica tiene poco incentivo económico para estudiarlas— con especial atención a las regiones donde los recursos médicos escasean.
Esa convicción tomó forma también en un libro que ella misma escribió, 'Born Incomplete, Made Perfect: The Miracle and Science of Being Her', donde entrelaza la experiencia de su hermana con la genética del síndrome de Turner, negándose a separar la narrativa personal del rigor científico. Antes de su ingreso a Sigma Xi, ya había recibido el International Leader Award en diciembre de 2025 y el máximo galardón de la Federación Interamericana de Periodismo en febrero de 2026.
Voluntaria de la Cruz Roja colombiana desde los trece años, Anillo no concibe el laboratorio y el servicio comunitario como caminos distintos, sino como expresiones de una misma certeza: que el conocimiento científico solo cumple su promesa cuando llega a quienes más lo necesitan. Su trayectoria, todavía en sus primeros capítulos, apunta hacia un modelo en que el rigor, el liderazgo social y el compromiso humano no compiten, sino que se refuerzan mutuamente.
At twenty-two years old, María del Rosario Yanett Anillo has joined one of the world's most selective scientific societies. Sigma Xi, founded in the United States in 1886, extends membership by invitation alone—a recognition reserved for researchers of exceptional caliber. The organization counts more than two hundred Nobel laureates among its ranks, including Albert Einstein and Linus Pauling. Anillo's admission marks her entry into that rarefied circle.
A biologist from Samaria, Colombia, Anillo graduated from Fordham University in New York and has already built a research portfolio that caught the attention of Sigma Xi's selection committee. Her work centers on genetics, infectious diseases in vulnerable populations, and the architecture of health systems across Latin America. At an age when most scientists are still in graduate school, she has positioned herself at the intersection of fundamental research and public health equity.
The arc of her career began with a personal reckoning. When her younger sister received a diagnosis of Turner syndrome, a genetic condition affecting chromosomal development, Anillo's intellectual curiosity crystallized into purpose. She has since devoted her research to genetic diseases, cancer, and rare conditions—what the medical world calls orphan diseases because they affect so few people that pharmaceutical companies have little financial incentive to study them. Her work aims to make visible the patients living with these diagnoses, particularly in regions where medical resources are thin.
That commitment took written form in a book she authored titled "Born Incomplete, Made Perfect: The Miracle and Science of Being Her." The work weaves together her sister's experience with the genetics underlying Turner syndrome, grounding scientific explanation in the texture of family life and medical uncertainty. It is the kind of writing that refuses the false boundary between personal narrative and rigorous science.
Before her Sigma Xi admission, Anillo had already accumulated other recognitions. In December 2025, she received the International Leader Award in the United States. Four months later, in February 2026, the Inter-American Federation of Journalism presented her with Colombia's Highest Award for her pioneering work in genetics across the region. These accolades suggest that her peers and institutions have already recognized what Sigma Xi's invitation now formally confirms: that she represents something worth watching.
Beyond the laboratory and the page, Anillo has volunteered with the Colombian Red Cross since she was thirteen years old. The volunteer work and the research are not separate tracks in her life—they are expressions of the same conviction, that scientific knowledge means little if it does not eventually reach the people who need it most. Her trajectory, still in its early chapters, demonstrates a model in which scientific rigor, social leadership, and human commitment do not compete for attention but reinforce one another. What she does next will likely shape how genetic research and public health advocacy develop in Latin America.
Notable Quotes
Her trajectory demonstrates how scientific research, social leadership, and humanitarian commitment can converge to address health disparities in underserved regions— Editorial summary of her work
The Hearth Conversation Another angle on the story
What made her choose genetics, specifically, when she could have pursued any field of biology?
Her sister's diagnosis was the catalyst. Turner syndrome is rare enough that most people have never heard of it, but common enough that thousands of families live with its consequences. That gap—between the medical reality and the public awareness—became her question.
Sigma Xi is extraordinarily selective. What do you think distinguished her application?
She wasn't just publishing papers. She was writing a book that connected genetic science to lived experience. She was working in Latin America, where the research infrastructure is thinner. She was doing this at twenty-two. The society doesn't just reward brilliance; it rewards the kind of brilliance that might change how science gets done.
The volunteer work with the Red Cross since age thirteen—is that just resume-building, or something deeper?
It's the opposite of resume-building. It's the thing that makes the research matter. You don't spend a decade in humanitarian work and then suddenly become a geneticist. You become a geneticist because you've already seen what happens when people don't have access to medical knowledge.
What does admission to Sigma Xi actually change for her?
Practically, it opens doors—funding, collaborations, visibility at a global scale. But more than that, it's institutional validation that her approach—science plus advocacy plus storytelling—is legitimate, is necessary. It tells her she's not choosing between being a scientist and being a human.
Her sister's condition is rare. Does that limit the scale of her impact?
Rare diseases affect millions of people worldwide. And the methods she develops for understanding Turner syndrome can apply to other genetic conditions. But more importantly, rare disease research often drives innovation in genetics itself. The constraints force you to think more carefully.